Update on Treatment and Prevention of Chronic Antibody Mediated Rejection in Renal Transplant Recipients
DOI:
https://doi.org/10.53778/pjkd40353کلمات کلیدی:
Rejection, kidney transplant, acute rejection, chronic rejection, antibody mediated rejection, complement,, plasmapheresis, Bortezomib,, Rituximab, Eculizumab, Tocilizumabچکیده
Chronic antibody mediated rejection (AMR) is a major cause of allograft failure1,2. Chronic AMR clinically presents with proteinuria and gradual decline in renal function. The underlying mechanisms of AMR include both antibody mediated complement-dependent cytotoxicity, complement-independent cellular cytotoxicity and other mechanisms. The purpose of this review is to appraise recent literature on diagnosis, treatment and prevention of chronic AMR.
دانلودها
چاپ شده
2021-01-31
شماره
نوع مقاله
Review Article
مجوز
حق نشر 2021 Salman Tahir Shafi
این پروژه تحت مجوز بین المللی Creative Commons Attribution-NonCommercial 4.0 می باشد.
نحوه استناد به مقاله
Update on Treatment and Prevention of Chronic Antibody Mediated Rejection in Renal Transplant Recipients. (2021). Pakistan Journal of Kidney Diseases, 4(03). https://doi.org/10.53778/pjkd40353
